无创正压通气联合醒脑静治疗慢性阻塞性肺疾病肺性脑病的疗效观察

Efficacy of non-invasive positive pressure ventilation combined with Xingnaojing for treatment of chronic obstructive pulmonary disease and pulmonary encephalopathy

目的观察无创正压通气联合醒脑静治疗慢性阻塞性肺疾病(COPD)肺性脑病的临床疗效。方法选择COPD合并肺性脑病患者60例,随机分为观察组和对照组,每组30例,两组患者均给予常规治疗及呼吸机无创正压通气,观察组加用醒脑静注射液静脉滴注,两组疗程均为5d,比较两组患者的临床疗效及治疗前后格拉斯哥昏迷量表(GCS)评分、pH值、PaO2值、PaCO2值的差异。结果观察组总有效率为93.3%,高于对照组的73.3%(P<0.05);治疗后,两组患者GCS评分、pH值、PaO2值均升高,PaCO2值均下降,并且观察组患者GCS评分、PaO2、PaCO2改善优于对照组(P<0.05)。结论无创正压通气联合醒脑静治疗COPD肺性脑病的临床疗效好,能促进患者意识障碍恢复,并改善呼吸功能。

Objective To observe the clinical efficacy of non-invasive positive pressure ventilation combined with Xingnaojing for the treatment of chronic obstructive pulmonary disease(COPD) and pulmonary encephalopathy. Methods Sixty patients with COPD complicated with pulmonary encephalopathy were randomly divided into observation group and control group,with 30 cases in each group.Both groups were given routine treatment and ventilator for non-invasive positive pressure ventilation,in addition,the observation group received intravenous drip of Xingnaojing Injection.The treatment lasted for 5 days in both group.The two groups were compared with respect to clinical efficacy ,and the difference between pre- and post-treatment Glasgow Coma Scale(GCS) score,pH value,PaO 2 value and PaCO 2 value. Results The total effective rate in the observation group was higher than that in the control group (93.3% vs. 73.3%, P <0.05);after treatment,GCS score,pH value,PaO 2 value increased but PaCO 2 value decreased in both groups,and the observation group had superior improvements in GCS score,PaO 2 and PaCO 2 than the control group( P <0.05). Conclusion Non-invasive positive pressure ventilation combined with Xingnaojing has a favorable clinical efficacy for the treatment of COPD and pulmonary encephalopathy,which can promote consciousness disorder recovery and improve respiratory function in the patients.